Gina L. Eagle

Gina L. Eagle

Auto-generated profile, based on publicly available information

Gina L. Eagle

Insmed Incorporated , Bridgewater , NJ , USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2019 in Hepatology
Verified
Journal Article
Open access
PDF file
MOMonday O. Ogese
Monday O. Ogese
RJRosalind E. Jenkins
Rosalind E. Jenkins
KAKareena Adair
Kareena Adair
ATArun Tailor
Arun Tailor
XMXiaoli Meng
Xiaoli Meng
CBCatherine Betts
Catherine Betts
Idiosyncratic drug‐induced liver injury (DILI) is a rare, often difficult‐to‐predict adverse reaction with complex pathomechanisms. However, it is now evident that certain forms of DILI are immune‐mediated and may involve the activation of drug‐specific T cells. Exosomes are cell‐derived vesicles that carry RNA, lipids, and protein cargo from their cell of origin to distant cells, and they may play a role in immune activation. Herein, primary human hepatocytes were treated with drugs associated with a high incidence of DILI (flucloxacillin, amoxicillin, isoniazid, and nitroso‐sulfamethoxazole) to characterize the proteins packaged within exosomes that are subsequently transported to dendritic cells for processing. Exosomes measured between 50 and 100 nm and expressed enriched CD63. Liquid chromatography–tandem mass spectrometry (LC/MS‐MS) identified 2,109 proteins, with 608 proteins being quantified across all exosome samples. Data are available through ProteomeXchange with identifier PXD010760. Analysis of gene ontologies revealed that exosomes mirrored whole human liver tissue in terms of the families of proteins present, regardless of drug treatment. However, exosomes from nitroso‐sulfamethoxazole‐treated hepatocytes selectively packaged a specific subset of proteins. LC/MS‐MS also revealed the presence of hepatocyte‐derived exosomal proteins covalently modified with amoxicillin, flucloxacillin, and nitroso‐sulfamethoxazole. Uptake of exosomes by monocyte‐derived dendritic cells occurred silently, mainly through phagocytosis, and was inhibited by latrunculin A. An amoxicillin‐modified 9‐mer peptide derived from the exosomal transcription factor protein SRY (sex determining region Y)‐box 30 activated naïve T cells from human leukocyte antigen A*02:01–positive human donors. Conclusion: This study shows that exosomes have the potential to transmit drug‐specific hepatocyte‐derived signals to the immune system and provide a pathway for the induction of drug hapten‐specific T‐cell responses.

1 April 2015 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
GEGina L. Eagle
Gina L. Eagle
JZJianguo Zhuang
Jianguo Zhuang
RJRosalind E. Jenkins
Rosalind E. Jenkins
KTKathleen J. Till
Kathleen J. Till
PJPuthen Veettil Jithesh
Puthen Veettil Jithesh
APAndrew R. Pettitt
Andrew R. Pettitt
The mutational status of the immunoglobulin heavy chain variable region defines two clinically distinct forms of chronic lymphocytic leukemia (CLL) known as mutated (M-CLL) and unmutated (UM-CLL). To elucidate the molecular mechanisms underlying the adverse clinical outcome associated with UM-CLL, total proteomes from nine UM-CLL and nine M-CLL samples were analyzed by isobaric tags for relative and absolute quantification (iTRAQ)-based mass spectrometry. Based on the expression of 3521 identified proteins, principal component analysis separated CLL samples into two groups corresponding to immunoglobulin heavy chain variable region mutational status. Computational analysis showed that 43 cell migration/adhesion pathways were significantly enriched by 39 differentially expressed proteins, 35 of which were expressed at significantly lower levels in UM-CLL samples. Furthermore, UM-CLL cells underexpressed proteins associated with cytoskeletal remodeling and overexpressed proteins associated with transcriptional and translational activity. Taken together, our findings indicate that UM-CLL cells are less migratory and more adhesive than M-CLL cells, resulting in their retention in lymph nodes, where they are exposed to proliferative stimuli. In keeping with this hypothesis, analysis of an extended cohort of 120 CLL patients revealed a strong and specific association between UM-CLL and lymphadenopathy. Our study illustrates the potential of total proteome analysis to elucidate pathogenetic mechanisms in cancer.

1 August 2010 in Cancer Letters
Verified
Journal Article
Closed access
VHVictoria C. Hodgkinson
Victoria C. Hodgkinson
GEGina L. Eagle
Gina L. Eagle
PDPhilip J. Drew
Philip J. Drew
MLMichael J. Lind
Michael J. Lind
LCLynn Cawkwell
Lynn Cawkwell

1 February 2010 in Lung Cancer
Verified
Journal Article
Closed access
SOSara L. O’kAne
Sara L. O’kAne
GEGina L. Eagle
Gina L. Eagle
JGJohn Greenman
John Greenman
MLMichael J. Lind
Michael J. Lind
LCLynn Cawkwell
Lynn Cawkwell

10 June 2019 in Journal of Medical Economics
Verified
Journal Article
Open access
TMTheodore K. Marras
Theodore K. Marras
MMMehdi Mirsaeidi
Mehdi Mirsaeidi
CVChristopher Vinnard
Christopher Vinnard
ECEdward D. Chan
Edward D. Chan
GEGina Eagle
Gina Eagle
ZQZHANG QUANWU
ZHANG QUANWU
Background: The prevalence of nontuberculous mycobacterial lung disease (NTMLD) in the United States (US) has increased; however, data characterizing the associated healthcare utilization and expenditure at the national level are limited. Objective: To examine associations between economic outcomes and the use of anti-Mycobacterium avium complex (MAC) guidelines-based treatment (GBT) for newly diagnosed NTMLD in a US national managed care claims database (Optum® Clinformatics® Data Mart). Methods: NTMLD was defined as having ≥2 claims for NTMLD (ICD-9 031.0; ICD-10 A31.0) on separate occasions ≥30 days apart (between 2007 and 2016). The cohort included patients insured continuously over a period of at least 36 months (12 months before initial NTMLD diagnostic claim and for the subsequent 24 months). Treatment was classified as GBT (consistent with American Thoracic Society/Infectious Diseases Society of America guidelines), non-GBT, or untreated. All-cause hospitalization rates and total healthcare expenditures at Year 2 were assessed as outcomes of the treatment prescribed in Year 1 after NTMLD diagnosis. Results: A total of 1039 patients met study criteria for NTMLD (GBT, n = 294; non-GBT, n = 298; untreated, n = 447). After adjustment for baseline characteristics, GBT was associated with a significantly lower all-cause hospitalization risk versus non-GBT (odds ratio [OR] = 0.53; 95% CI, 0.33-0.85, P = 0.008), and versus being untreated (OR =0.57; 95% CI, 0.35-0.91, P = 0.020). Adjusted total healthcare expenditure in Year 2 with GBT ($69,691) was lower than that with non-GBT ($77,624) with a difference of −$7933 (95% CI, −$14,968 to −$899; P = 0.03). Conclusions: Patients with NTMLD in a US managed claims database who were prescribed GBT had lower hospitalization risk than those who were prescribed non-GBT or were untreated. GBT was associated with lower total healthcare expenditure compared with non-GBT.

1 October 2013 in Journal of Proteomics
Verified
Journal Article
Closed access
EKElena Kashuba
Elena Kashuba
GEGina L. Eagle
Gina L. Eagle
JBJames Bailey
James Bailey
PEPaul Evans
Paul Evans
KWKevin J. Welham
Kevin J. Welham
LCLynn Cawkwell
Lynn Cawkwell